The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Mineral Density( BMD) and Rheumatoid Arthritis (RA)
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Denosumab (Primary) ; Etanercept
- Indications Postmenopausal osteoporosis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 08 Mar 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 22 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.